Precision Medicine A New Initiative. The Concept of Precision Medicine (PM) The prevention and treatment strategies that take individual variability into.

Slides:



Advertisements
Similar presentations
Mental health strategy of the Medical Research Council (UK) Opportunities for European engagement and a role of FEAM European Parliament 22 nd March 2011.
Advertisements

PERSONALIZED MEDICINE: Planning for the Future You, Your Biomarkers and Your Rights.
Retreat Topics iPSC Opportunities in NIAMS Diseases Science Management Forum: Leveraging and Strategic Funding Collaborations Atopic Dermatitis Advancing.
Clinical Implementation of Genomic Cancer Medicine
NHLBI Strategic Visioning Process: Charting Our Future Together
Wrapup. NHGRI strategic plan What does the NIH think genomics should be for the next 10 years? [Nature, Feb. 2011]
Doug Brutlag 2011 Genomics Bioinformatics & Medicine Biochem 158/258 and HumBio 158G Doug.
1 Biomedical Sciences Public and Environmental Health Regenerative Medicine Translational Research.
Introduction of Cancer Molecular Epidemiology Zuo-Feng Zhang, MD, PhD University of California Los Angeles.
Personalized Medicine
Clinical Perspective. Screening/Prevention Who is at risk for what type Decision to Intervene: Risk Assessment normal Evidence of Disease Disability Death.
Challenge of personalized health care: To what extent is medicine already individualized and what are the future trends? Author: Walter Fierz Presented.
Genetic Testing in Genomic Medicine Gail H. Vance M.D. Professor, Department of Medical & Molecular Genetics Indiana University School of Medicine.
Cancer Clinical Trials:
Introduction to Molecular Epidemiology Jan Dorman, PhD University of Pittsburgh School of Nursing
Health Promotion Model
Clinical Pharmacy Basma Y. Kentab MSc..
Presented by Karen Xu. Introduction Cancer is commonly referred to as the “disease of the genes” Cancer may be favored by genetic predisposition, but.
The NIH Roadmap for Medical Research
Paola CASTAGNOLI Maria FOTI Microarrays. Applicazioni nella genomica funzionale e nel genotyping DIPARTIMENTO DI BIOTECNOLOGIE E BIOSCIENZE.
University of Utah Department of Human Genetics Pharmacogenomics Louisa A. Stark, Ph.D. Director.
Cancer Vaccines Medicines that belong to a class of substances known as biological response modifiers. Biological response modifiers stimulate or restore.
Genomics Alexandra Hayes. Genomics is the study of all the genes in a person, as well as the interactions of those genes with each other and a person’s.
Copyright © 2014 Oracle and/or its affiliates. All rights reserved. | Oracle Health Sciences Global Business Unit Strategy Steve Rosenberg Senior Vice.
European Health Forum Gastein, Bad Hofgastein, Austria, September 2002 Towards the Sixth Framework Programme Parallel Forum V 26 September 2002 Public.
Science, research and developmentEuropean Commission Chile-EC S&T Agreement Brussels, 24 September 2002 Life Sciences, Genomics and Biotechnology for Health.
Anticipated FY2016 Appropriations Agency$ Million NIH200 Cancer70 Cohort130 FDA10 Office of the Natl Coord. for Health IT (ONC) 5 TOTAL215 Mission: To.
Evidence-Based Public Health Nancy Allee, MLS, MPH University of Michigan November 6, 2004.
The Value of Tissue Banks to Drug and Dx Developers Barbara L. Handelin, Ph.D. Conflicts of Interest, Privacy/Confidentiality, and Tissue Repositories:
The Use of Predictive Biomarkers in Clinical Trial Design Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute
Wisconsin Genomics Initiative W isconsin M edical R esearch T riangle Wisconsin Medical Discovery Triangle.
Bringing Genomics Home Your DNA: A Blueprint for Better Health Dr. Brad Popovich Chief Scientific Officer Genome British Columbia March 24, 2015 / Vancouver,
Genomics, Medicine, and Society American College of Radiology May 13, 2003 Francis S. Collins, M.D., Ph.D.
Joe Pekny, Professor Chemical Engineering Director, e-Enterprise Center Discovery Park Marietta Harrison, Professor Medicinal Chemistry & Molecular Pharmacology.
Leading the Biomedical Revolution in Precision Health: How Stanford Medicine is Developing the Next Generation of Health Care Annual Stanford Medicine.
D4FF55A0-6B6F BF422A9BA9 Present by: Xiao Chen On December 7, 2015.
Cancers of the Digestive System November 19, 2007 NCDD Meeting Chair: John M. Carethers, MD Vice Chair: Robert Sandler, MD, MPH.
Introduction to Public Health Nutrition January 2012 Nutrition 531.
TMO Review Jin Guang Zheng, Tetherless World Constellation.
Biotechnology Industry Organization (BIO) Risk Management Public Workshop Day 1 - April 9, 2003 Risk Assessment in Drug and Biological Development Joanna.
Consumer Advocate Perspective Clinical Trials Registration Sharon F. Terry, JAM Sharon F. Terry, JAM President and CEO, Genetic Alliance, Inc. Founding.
Scientific investigations & work from many fields to improve the health and well being of humans and animals.
INTERPRETING GENETIC MUTATIONAL DATA FOR CLINICAL ONCOLOGY Ben Ho Park, M.D., Ph.D. Associate Professor of Oncology Johns Hopkins University May 2014.
“Translational research includes two areas of translation. One (T1) is the process of applying discoveries generated during research in the laboratory,
1 Modelling and Simulation EMBL – Beyond Molecular Biology Physics Computational Biology Chemistry Medicine.
Technology of healthcare  BY: seemeka Johnson. Technology of healthcare Doctors now know that genetics play a part in possibly passing on diseases from.
Direct-to-Consumer Genetic Testing: Outputs from the EASAC-FEAM Working Group Martina Cornel VU University Medical Center, Amsterdam.
Bringing Genomics Home Your DNA: A Blueprint for Better Health Genome British Columbia November 18, 2015 / West Vancouver, BC.
Doug Brutlag 2011 The impact of genomics on the future of medicine and health Muhammad Faisal 2015-Arid-3638 PhD(scholar) Biochemistry.
A Genomics-Enabled Rapid Learning Health System Goals for 2015 & 2016 Lynn Etheredge IOM – December 8, 2014.
Moiz Bakhiet, MD, PhD, Professor and Chairman
New research areas in personalised medicines
To develop the scientific evidence base that will lessen the burden of cancer in the United States and around the world. NCI Mission Key message:
Bringing Genomics Home Your DNA: A Blueprint for Better Health
Precision Medicine, Community Engagement, and Native Health
PhD fellowship in bioinformatics
FP6 Priority 1, Life Sciences Genomics and Biotechnology for Health
National and International Efforts worth knowing about
Innovative Approaches to Clinical Trials
Precision Medicine / Precision Health
Precision Oncology Carolyn M. Hutter, PhD.
Knowledge l Action l Impact
The Genomics of Cancer and Molecular Testing:
From Data to Therapies Research in Xinghua Lu’s Lab
Introduction to Public Health Nutrition
Implementing Genome-Driven Oncology
Clinical Genomics in Inflammatory Bowel Disease
Precision Medicine A New Era Hazem Assi American University of Beirut
FP6 Priority 1, Life Sciences Genomics and Biotechnology for Health
Aaron Ritter MD Cleveland Clinic Lou Ruvo Center for Brain Health
Presentation transcript:

Precision Medicine A New Initiative

The Concept of Precision Medicine (PM) The prevention and treatment strategies that take individual variability into account.

The prospect of applying PM broadly has been dramatically improved by: 1.The development of large-scale biologic databases (such as the human genome sequence) 2.Patient characterization such as proteomics, metabiolomics, genomics, cellular assays, and mobile health technology 3.Computational tools for the analysis of large data sets

Oncology is well suited for studying the near-term impact of PM Research has revealed many of the molecular lesions that drive cancers. Each cancer has its own genomic signature, with tumor-specific features and features common to multiple tumor types. Cancers are a consequence of accumulating genomic damage. Inherited genetic variations contribute to cancer risk. This understanding has influenced risk assessment, diagnostic categories, and therapeutic strategies. Drugs and antibodies have been developed designed to counter specific molecular drivers. Molecular signatures may be strong predictors of benefit.

Cancer-focus is designed to address obstacles encountered in “Precision Oncology”: 1.Unexplained drug resistance 2.Genomic heterogeneity of tumors 3.Insufficient means for monitoring responses and tumor recurrence 4.Limited knowledge about the use of drug combinations

PM’s more individualized, molecular approach may: 1.Modify, but not replace, prevention, diagnostics, screening, and effective treatments 2.May provide a framework for accelerating the adoption of precision medicine in inherited genetic disorders and infectious diseases

The Precision Medicine Initiative will generate the scientific evidence needed to move the concept of precision medicine into clinical practice.

NEAR TERM GOALS Innovative clinical trials of targeted drugs for adult, pediatric cancers Use of combination therapies Knowledge to overcome drug resistance

LONGER TERM GOALS Create a research cohort of > 1 million American volunteers who will share genetic data, biological samples, and diet/lifestyle information, all linked to their electronic health records if they choose.

Pioneer a new model for doing science that emphasizes engaged participants, responsible data sharing, and privacy protection. Research based upon the cohort data will: 1.Advance pharmacogenomics, the right drug for the right patient at the right dose 2.Identify new targets for treatment and prevention 3.Test whether mobile devices can encourage healthy behaviors 4.Lay scientific foundation for precision medicine for many diseases LONGER TERM GOALS

?’s